Aligos Therapeutics Inc Ordinary Shares ALGS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $5.51
- Day Range
- $5.25–6.15
- 52-Week Range
- $3.98–13.69
- Bid/Ask
- $5.50 / $5.96
- Shares Outstanding
- 6.24M
- Market Cap
- $34.91M
- Volume/Avg
- 335,799 / 177,370
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.86
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 82
- Website
- https://www.aligos.com
Valuation
|
Metric
|
ALGS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.11 |
Price/Sales | 1.86 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ALGS
|
|---|---|
Quick Ratio | 2.05 |
Current Ratio | 2.19 |
Interest Coverage | — |
Quick Ratio
ALGS
Profitability
|
Metric
|
ALGS
|
|---|---|
Return on Assets (Normalized) | −79.98% |
Return on Equity (Normalized) | −127.54% |
Return on Invested Capital (Normalized) | −120.88% |
Return on Assets
ALGS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<D$!><m | LOCK|sv?Q> | $126B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|BS!PCB^ | LOCK|ctcj | $81B | |||
| argenx SE ADR
ARGX
| LOCK|VRW%r@R | LOCK|Ym | $55B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!<@>VZh | LOCK|^<wG% | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|VpXq@N | LOCK|%? | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#>HvVZp | LOCK|s#<? | $29B | |||
| Incyte Corp
INCY
| LOCK|FSg>>Z | LOCK|m<T | $24B | |||
| Moderna Inc
MRNA
| LOCK|Nm$pXJ | LOCK|%& | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|>#j#yz | LOCK|@@ | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|s<K^!$Q | LOCK|@F | $17B |
United States